Table 5.
Univariate analysis of survival
| Variable | OS | PFS | ||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| Age, y | 1.02 (0.94‐1.09) | 670 | 1.02 (0.96‐1.07) | 571 |
| Refractory or relapsed (Ref: newly diagnosed) | 1.25 (0.24‐6.45) | 792 | 2.25 (0.73‐6.91) | 157 |
| Male gender (Ref: female) | 0.63 (0.12‐3.27) | 585 | 0.78 (0.21‐2.83) | 703 |
| Primary site is URT (Ref: non‐URT) | 0.75 (0.15‐3.88) | 754 | 0.73 (0.22‐2.36) | 596 |
| Disease stage (Ref: stage I) | ||||
| II | 0.79 (0.11‐5.64) | 816 | 1.35 (0.32‐5.66) | 679 |
| III or IV | 0.81 (0.14‐4.87) | 820 | 0.85 (0.20‐3.54) | 818 |
| ECOG performance status ≥ 1 (Ref: 0) | 0.87 (0.39‐1.97) | 744 | 0.95 (0.32‐2.82) | 921 |
| IPI score (Ref: IPI = 0) | ||||
| 1 | 1.47 (0.15‐14.14) | 739 | 3.29 (0.40‐27.37) | 270 |
| ≥2 | 2.17 (0.22‐20.9) | 504 | 4.37 (0.52‐36.39) | 173 |
| Elevated LDL cholesterol (Ref: normal) | 0.56 (0.13‐2.52) | 451 | 0.67 (0.23‐2.01) | 480 |
| Elevated ferroprotein (Ref: normal) | 1.08 (0.21‐5.58) | 926 | 1.48 (0.41‐5.39) | 550 |
| Elevated β‐microglobulin (Ref: normal) | 6.1 (0.73‐50.75) | 094 | 1.28 (0.43‐3.80) | 662 |
| Ki‐67‐positive cells > 60% (Ref: ≤60%) | 0.43 (0.08‐2.23) | 316 | 0.87 (0.29‐2.60) | 808 |
| CD56 (+) (Ref: negative) | 0.69 (0.08‐5.71) | 728 | 1.75 (0.23‐13.43) | 593 |
| CD3 (+) (Ref: negative) | 0.99 (0.12‐8.22) | 992 | 2.63 (0.34‐20.26) | 354 |
| TCR (+) (Ref: negative) | 1.76 (0.21‐14.67) | 600 | 1.98 (0.44‐8.94) | 376 |
| B symptoms (Ref: none) | 1.09 (0.21‐5.64) | 922 | 0.82 (0.25‐2.71) | 748 |
Abbreviations: CD, cluster of differentiation; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; IPI, international prognostic index; LDL, low‐density lipoprotein; NA, data not available owing to no events in the referent group or in the reference group; OR, odds ratio; OS, overall survival; PFS, progression‐free survival; Ref, referent group; TCR, T‐cell receptor; URT, upper respiratory tract.